Expanded indications for LiquiBand Fix 8
1 May 2015
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Expanded indications for LiquiBand® Fix 8™
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that additional clinical work has been completed to allow for expanded indications of LiquiBand® Fix 8™, the Group’s newly developed cyanoacrylate adhesive device for hernia mesh fixation. The device is now able to be used for the laparoscopic surgical mesh fixation for all types of abdominal hernia as well as for the closure of the membrane lining the abdominal wall (peritoneum).
LiquiBand® Fix 8™, an innovative device which augments AMS’s existing LiquiBand® range of topical tissue adhesive products, was developed by AMS to enable the laparoscopic attachment of hernia meshes within the body through the accurate delivery of individual drops of cyanoacrylate adhesive. This accurate laparoscopic application of adhesive is expected to reduce surgical complications, in particular the potential pain associated with the use of tacks and staples, thereby improving the patient experience and reducing healthcare costs overall.
LiquiBand® Fix 8™ received CE approval in May 2014, allowing the product to be used for the laparoscopic repair of hernias occurring in the groin, which account for 75% of all hernias. The device has been marketed and distributed by the Group’s direct sales teams in the UK and Germany and through various distributor partners across the EU. The applications of LiquiBand® Fix 8™ have now been extended for the laparoscopic repair of all abdominal hernias and for the closure of the membrane lining of the abdominal wall which may need repairing as a result of the hernia repair procedure.
Chris Meredith, Chief Executive Officer of AMS, commented: “LiquiBand® Fix 8™ is an important product for AMS and demonstrates our innovation and market agility. We are delighted with the response we have received following the launch from surgeons who have been extremely positive about the ease of use of this device and the benefit it brings to patients, reducing the pain that can be experienced when tacks or staples are used. This is the first extension of the claims of LiquiBand® Fix 8™ and we expect to develop further opportunities for this kind of application, broadening the market for the use of adhesives internally. This is an important part of our strategy to increase our penetration of the Operating Theatre segment of the wound closure market.”
– Ends –
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc
Chris Meredith, Chief Executive Officer
Mary Tavener, Group Finance Director
+44 (0) 1606 545508
Consilium Strategic Communications
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan
+44 (0) 20 3709 5700
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has more approximately 470 employees. For more information please see www.admedsol.com.
This information is provided by RNS